Healthcare / Medical DevicesUpdated 2026-05-10 22:07 UTC

BBNX stock hub

Beta Bionics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BBNXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

430M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BBNX

In the news

Latest news · BBNX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-22.7

P25 -105.6P50 -46.5P75 -3.1

ROIC-16.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BBNX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

196

Groups with data

Currency

USD

Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001674632
Company name	Beta Bionics, Inc.
Country	United States
Country code	US
Cusip	08659B102
Employees	423
Employees Change	129%
Employees Change Percent	43.88
Enterprise value	$237.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Medical Devices
IPO Date	2025-01-30
Isin	US08659B1026
Last refreshed	2026-05-10
Market cap	$430M
Market cap category	Small-Cap
Price	$9.65
Price currency	USD
Rev Per Employee	260,609.93x
Sector	Healthcare
Sic	3841
Symbol	BBNX
Website	https://www.betabionics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.45%
EV Sales Forward	1.62x
EV/Sales	2.15x
FCF yield	-14.21%
P/B ratio	1.59x
P/S ratio	3.9x
PS Forward	2.94x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-70.13%
EBITDA Margin	-68.45%
Gross margin	57.15%
Gross Profit	$63M
Gross Profit Growth	67.3%
Gross Profit Growth Q	83.22%
Net Income	$-66.4M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Pretax Margin	-60.27%
Profit Margin	-60.27%
Profit Per Employee	$-157,066
ROA	-15.04
ROCE	-27.49
ROE	-22.71
ROIC	-16.14

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-32.86%
EPS Growth Quarters	6
EPS Growth Years	1
Revenue Growth	57.87x
Revenue Growth Q	56.62x
Revenue Growth Quarters	6x
Revenue Growth Years	3x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.34
Assets	$304.4M
Cash	$199.5M
Current Assets	$248M
Current Liabilities	$23.2M
Debt	$6.9M
Debt Equity	$0.03
Equity	$271.2M
Liabilities	$33.2M
Long Term Assets	$56.4M
Long Term Liabilities	$10M
Net Cash	$192.6M
Net Cash By Market Cap	$44.79
Net Cash Growth	-14.21%
Net Debt Equity	$-0.71
Tangible Book Value	$271.2M
Tangible Book Value Per Share	$6.09

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.69
Inventory Turnover	2.39
Net Working Capital	$27.1M
Quick ratio	9.39
Working Capital	$224.8M
Working Capital Turnover	$0.47

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-250.6%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-32.85%
200-day SMA	19.05
50-day SMA	10.86
50-day SMA vs 200-day SMA	50under200
All Time High	32.71
All Time High Change	-70.5%
All Time High Date	2025-11-26
All Time Low	8.8
All Time Low Change	9.66%
All Time Low Date	2026-04-10
ATR	0.79
Beta1y	0.87
Beta2y	1.47
Ch YTD	-68.33
High	10.52
High52	32.71
High52 Date	2025-11-26
High52ch	-70.5%
Low	9.6
Low52	8.8
Low52 Date	2026-04-10
Low52ch	9.66%
Ma50ch	-11.13%
Premarket Change Percent	0
Premarket Price	$10.5
Price vs 200-day SMA	-49.34%
RSI	39.47
RSI Monthly	36.54
RSI Weekly	36.12
Sharpe ratio	-0.09x
Sortino ratio	-0.06
Total Return	-250.6%
Tr YTD	-68.33
Tr1m	-0.82%
Tr1w	-6.22%
Tr3m	-26.22%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	2
Analyst Price Target Top	$17
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.48
Earnings Revenue Estimate	27,280,560x
Earnings Revenue Estimate Growth	54.66x
Operating Income	$-77.3M
Operating margin	-70.13
Price target	$23.8
Price Target Change	$147
Price Target Change Top	$76.17

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	21,717,336%
Float Percent	48.74%
Shares Insiders	5.46%
Shares Institutions	75.67%
Shares Out	44,561,695
Shares Qo Q	0.55%
Shares Yo Y	250.6%
Short Float	32.86%
Short Ratio	6.28
Short Shares	16.02

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-80.1M
Average Volume	1,073,468.95x
Bv Per Share	6.09
CAPEX	$-6.3M
Ch1m	-0.82
Ch1w	-6.22
Ch1y	-32.85
Ch3m	-26.22
Ch6m	-63.31
Change	-8.1%
Change From Open	-8.1
Close	10.5
Days Gap	0
Depreciation Amortization	1,855,000
Dollar Volume	7,289,359.1
Earnings Date	2026-04-21
Earnings Time	amc
EBIT	$-77.3M
EBITDA	$-75.5M
EPS	$-1.51
F Score	2
FCF	$-61.1M
FCF EV Yield	-25.75x
FCF Per Share	$-1.37
Financing CF	4,378,000
Fiscal Year End	December
Founded	2,015
Investing CF	38,156,000
Ipr	-43.24
Iprfo	-56.14
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-21
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-24
Ma150	19.07
Ma150ch	-49.41%
Ma20	11.13
Ma20ch	-13.33%
Net CF	-12,248,000
Next Earnings Date	2026-07-28
Open	10.5
Optionable	Yes
Position In Range	5.43
Ppne	16,385,000
Pre Close	10.5
Price Date	2026-05-08
Ptbv Ratio	1.59
Relative Volume	0.7x
Revenue	110,238,000x
SBC By Revenue	17.22x
Share Based Comp	18,986,000
Tr6m	-63.31%
Us State	California
Volume	755,374
Z Score	13.15

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BBNX pay a dividend?

Capital-return profile for this ticker.

Performance

BBNX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BBNX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+75.7%

Float: +48.7% of shares outstanding

Insider ownership

+5.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BBNX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

39.5

Neutral momentum band

Price vs 200-day MA

-49.3%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.09

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BBNX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BBNX stock rating?

Beta Bionics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BBNX analysis?

The full report lives at /stocks/BBNX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BBNX?

The latest report frames BBNX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BBNX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.